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Abstract  
Larvae of Schistosoma (schistosomula) are highly susceptible to host immune responses and are 
attractive prophylactic vaccine targets, although cellular immune responses against schistosomula 
antigens in endemic human populations are not well characterized. We collected blood and stool 
from 54 Schistosoma mansoni-infected Ugandans, isolated peripheral blood mononuclear cells and 
stimulated them for 24 hours with schistosome adult worm and soluble egg antigens (AWA and 
SEA), along with schistosomula recombinant proteins rSmKK7, Lymphocyte Antigen 6 isoforms 
(rSmLy6A and rSmLy6B), tetraspanin isoforms (rSmTSP6 and rSmTSP7). Cytokines, chemokines and 
growth factors were measured in the culture supernatants using a multiplex luminex assay, and 
infection intensity was determined before and at one year after praziquantel (PZQ) treatment using 
the Kato Katz method. Cellular responses were grouped and the relationship between groups of 
correlated cellular responses and infection intensity before and after PZQ treatment investigated. 
AWA and SEA induced mainly Th2 responses. In contrast, rSmLy6B, rSmTSP6 and rSmTSP7 induced 
Th1/pro-inflammatory responses. While recombinant antigens rSmKK7 and rSmLy6A did not induce 
a Th1/pro-inflammatory response, they had an association with pre-treatment infection intensity 
after adjusting for age and sex. Testing more schistosomula antigens using this approach could 
provide immune-epidemiology identifiers necessary for prioritizing next generation schistosomiasis 
vaccine candidates.  
 
Keywords: Schistosoma mansoni, schistosomula, vaccine, cytokines, Th1/pro-inflammatory 
 
 
Introduction  
There are currently 206.4 million people suffering from schistosomiasis worldwide (1) with the 
majority of infected individuals living in Africa. National control programmes in high-risk countries 
such as Uganda treat infected school-age children and adults through mass drug administration 
(MDA), using the drug praziquantel (PZQ). Although the MDA programmes have a high coverage in 
the targeted areas, national coverage still remains relatively low. For instance, in 2015 just over a 
third of the estimated 13.2 million people who required treatment in Uganda were reported to have 
received it (1). In addition, MDA programmes have no effect on recurrent reinfections in hotspots of 
transmission(2). More unsettlingly, there are reports of reduced efficacy of PZQ with multiple rounds 
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of MDA (3,4). This suggests that MDA alone is insufficient to control morbidity and prevent 
schistosomiasis transmission. Therefore, an integrated approach with other interventions such as 
vaccines is required (5,6).  
 
A few schistosomiasis vaccines, such as Sh28GST, Sm-TSP-2 and Sm-14 are 
currently in early human clinical trials (7,8), although the trial data are not yet available. 
Therefore, novel schistosome vaccine antigens are still needed for the vaccine development 
pipeline. Schistosome larvae within the vertebrate host (known as schistosomula) are 
susceptible to host immune responses in animal models, and thus antigens from this stage are 
thought to be potential vaccine candidates (9–11). The schistosomula develop when infective 
free-swimming fresh-water larvae (cercariae) burrow through the host skin and lose their 
bifurcated tails in a process called transformation (12). Additional structural changes, such as 
the loss of the cercarial glycocalyx coat during the transformation process, expose the 
developing schistosomula to host-mediated immune responses. As the skin-stage 
schistosomula develop into the lung-stage schistosomula and adult worms, they acquire host 
antigens (13) masking themselves from host immune effector mechanisms (14). By targeting 
antigens from the early schistosomula, it might be possible to attack this stage and prevent 
infection of the host. Potential vaccine candidates expressed in the newly transformed 
schistosomula include SmKK7 (Smp_194830) (15,16), SmLy6A (Smp_019350) and 
SmLy6B (Smp_105220) (13,17) and the tetraspanins SmTSP6 (Smp_059530) and SmTSP7 
(Smp_099770) (18,19). 
 
SmKK7 is secreted by both the cercariae and the schistosomula (16); it has also been 
reported to be found in the nervous system of adult S. mansoni and to be homologous to a 
component in scorpion venom, acting as a potassium ion channel blocker. Schistosoma 
mansoni lymphocyte antigens rSmLy6A and rSmLy6B (also known as SmCD59a and 
SmCD59b), are members of the Three-Finger Protein Domain (TFPD) superfamily. Although 
they are homologous to the TFPD-containing human CD59, which protects human cells from 
complement fixation, rSmLy6A and rSmLy6B do not inhibit host complement fixation and as 
such their function remains unknown (20). rSmLy6A and rSmLy6B are highly expressed by 
the schistosomula, and as probable GPI-anchored proteins on the schistosome tegument, they 
likely interact directly with host immune cells (21). S. mansoni transmembrane proteins, 
tetraspanins rSmTSP6 and rSmTSP7, similarly to other tetraspanin family members, are 
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thought to be involved in cell membrane biology (19,22). As all of the proteins described 
above are at the interface between the parasite and the host immune system, and thus may be 
novel vaccine antigens, we assessed the cellular responses to these antigens in individuals 
residing in an S. mansoni endemic area.  
 
Materials and Methods  
Ethics Statement  
Ethical approval for the study was obtained from the Makerere University School of Biomedical 
Sciences Higher Degrees Research and Ethics Committee (reference number SBS 300) and the 
Uganda National Council for Science and Technology (reference number HS 1040). A signed 
informed consent form was obtained from participants, or parents or legal guardians of children 
below 18 years of age, for enrolment in the study. 
 
Recruitment of Study Participants 
We examined immune responses in peripheral blood mononuclear cells (PBMCs) of participants 
from TheSchistoVac study (http://www.theschistovac.eu) which aimed to develop safe candidates 
for a prophylactic schistosomiasis vaccine. The design of TheSchistoVac study is described elsewhere 
(23). Briefly, a cohort of 372 people from an S. mansoni endemic fishing village, Namoni, in Mayuge 
District, Eastern Uganda were recruited in September 2011; infected individuals were treated with 
two doses of PZQ (40 mg/kg) one week apart and followed-up at five weeks and at one year after 
PZQ treatment. Venous blood was drawn before treatment and peripheral blood mononuclear cells 
(PBMCs) isolated by density gradient centrifugation using Lymphoprep™ (STEMCELL Technologies 
Inc, USA) and cryopreserved in liquid nitrogen. Here, we report pre-treatment cellular immune 
responses in 54 participants from the cohort described above.  
 
Microscopic Examination of Stool for Ova  
Stool samples were collected before treatment (to determine pre-treatment infection intensity), five 
weeks after treatment (to examine effectiveness of the treatment) and at one year after PZQ 
treatment (to determine reinfection). Three stool samples were collected on three consecutive days 
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from study participants. Two thick smears were made from each of the stool sample, processed 
using the Kato Katz method (24) and examined under a light microscope to determine S. mansoni 
egg count.  
 
Schistosoma mansoni Antigens 
TheSchistoVac consortium provided the antigens used in this study. The antigens included S. 
mansoni adult worm antigen (AWA) (25) and S. mansoni soluble egg antigen (SEA) (25) as well as the 
S. mansoni schistosomula-enriched recombinant antigens rSmKK7 (smp_194830), rSmLy6A 
(smp_019350), rSmLy6B (smp_105220), rSmTSP6 (smp_059530) and rSmTSP7 (smp_099770) (19). 
The antigens used in the present study are summarised in Table 1. These antigens were identified as 
highly expressed products in the schistosomula life cycle stage after screening the Schistosoma 
transcriptome using a DNA microarray, as previously described (17,19). Specifically, a >5-fold 
increase in expression when comparing normalized expression averages from snail (egg, miracidia, 
mother sporocyst and daughter sporocyst) to schistosomula (3-hour, 24-hour, 3-day and 6-day 
schistosomula) life stages was observed (17). Recombinant antigens were expressed in Escherichia 
coli and purified using methods as previously described for rSmKK7 (14), rSmLy6A and rSmLy6B (15). 
For rSmTSP6 and rSmTSP7, 84 and 78 amino acids representing the extracellular loop 2 of these 
proteins respectively as defined by TMHMM2.0 software (26) About 106-189 amino acid of rSmTSP6 
and 108-185 amino acid of rSmTSP7 were expressed using the same vector, expression parameters 
and purification methods as rSmLy6A and B (27). Endotoxin contamination of the recombinant 
antigens was determined by Limulus amebocyte lysate (LAL) assay using the Pierce LAL chromogenic 
endotoxin quantitation kit (Thermo Fisher, US). The endotoxin levels were 7.56 endotoxin units 
(EU)/mg for rSmKK7, undetectable (< 0.4 EU/mg) for rSmLy6A, 0.892 EU/mg for rSmLy6B, 0.626 
EU/mg for rSmTSP6 and 0.42 EU/mg for rSmTSP7. The limit of detection of the LAL assay was 0.4 
EU/mg.  
 
PBMC Stimulation  
Peripheral blood mononuclear cells were thawed, rested for six hours and stimulated for 24 hours 
with a panel of S. mansoni antigens in RPMI 1640 Medium (Thermo Fischer, US): AWA (10µg/ml), 
SEA (10µg/ml), rSmKK7 (2 µg/ml), rSmLy6A (2 µg/ml), rSmLy6B (2 µg/ml), rSmTSP6 (2 µg/ml) and 
rSmTSP7 (2 µg/ml). Due to a limited number of PBMCs available per individuals and a large number 
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of antigens tested, each antigen was tested in singlicate. After 24 hours, the supernatants were 
collected and stored at -80°C. Medium without stimulus was used as a negative control. 
 
Multiplex Luminex Assay 
Supernatants were analysed for cytokines (IFN-, L-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-
12, IL-13, IL-15, IL-17 and TNF), chemokines (Eotaxin, IL-8, IP-10, MCP-1, MIP1a, MIP1b, RANTES) and 
growth factors (bFGF, GCSF, GMCSF, PDGFbb, VEGF) using a commercial Bio-Plex Luminex assay (Bio-
Rad, USA) according to the manufacturers’ recommendations, and acquired using Bio-Plex 200 
System (Bio-Rad, USA). Samples below the limit of detection were assigned values corresponding to 
half of the lowest standard value and those above the highest limit of detection were given the value 
of the highest standard. Cytokines that were wholly below the lower limit of the assay (IL-4 and IL-7) 
and chemokines wholly above the upper limit of the assay (MIP1α, MIP1β and RANTES) were 
excluded from analysis. Samples from unstimulated PBMCs that produced TNF levels greater than 
100pg/ml were also excluded from analysis, as these were considered unreliable (28,29); high IL-1 
and IL-1ra levels were observed in the same samples. 
 
Statistical Data Analysis 
Statistical analysis was carried out using STATA version 13 (StataCorp, USA) and graphs drawn using 
GraphPad Prism version 6.0g (GraphPad Software Inc., USA). Cytokine, chemokine and growth factor 
levels were not normally distributed and were, therefore, transformed using Box-Cox transformation 
(30,31). The paired Student’s T-test was used to compare responses between antigen stimulated and 
unstimulated PBMCs. Because the mean cytokine/chemokine/growth factor levels of more than two 
antigen stimulated PBMCs was compared to that of the unstimulated PBMCs, the error rate due to 
multiple testing was adjusted by considering a Bonferroni correction, taking into account the 
number of comparisons being made. In this instance, a p-value of 0.007 (= 0.05/7, the number of 
antigens in the study) for each cytokine/chemokine/growth factor was taken to be statistically 
significant. Responses showing significant variation from the unstimulated PBMCs were further 
analysed. Unsupervised hierarchical clustering of the immune responses using Spearman correlation 
as the measure of similarity was performed using GENE-E (Broad Institute Inc., USA). The association 
between clusters (groups of correlated immune parameters) and infection intensity before 
treatment and following treatment were investigated using the global test version 5.29.1. The global 
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test was based on the logistic regression model and was implemented in R version 3.3.2 (The R 
Foundation). For this analysis, the post-treatment infection intensity of the participants was 
classified into two groups light and moderate to heavy infection intensity rather than the WHO 
categories (light/moderate/heavy infection intensity) as when stratified by the three WHO 
categories there were insufficient numbers within the moderate and heavy infection intensity 
groups for statistical analysis.  
 
Results 
Characteristics of the Study Population 
Table 2 shows the demographics of the study population. The age range of the study participants 
was 6-40 years and 28 (51.9%) were female. All study participants were infected with S. mansoni 
with most individuals having heavy infection intensity (76%) at baseline. The median infection 
intensity was 1412 ((interquartile range 443-2567) eggs per gram of stool at baseline. Five weeks 
after PZQ treatment, all the participants had zero eggs, indicative of treatment success (data not 
shown). At follow-up (one year after PZQ treatment), all participants were re-infected with most 
(57.0%) having a light infection intensity.  
 
Schistosoma mansoni Adult Worm and Egg Antigens Induce Th2 Responses  
Whole parasite preparations of S. mansoni, particularly the egg antigens, are known to induce Th2 
responses (27-29). We sought to validate our protocol by examining immune responses to crude 
parasite preparations of AWA and SEA. As expected, and confirming our analysis approach, the adult 
worm and soluble egg antigens induced the production of significant levels of IL-5 and IL-13 
compared to medium (Figure 1). None of the schistosomula antigens induced significant Th2 
cytokine production, with the exception of rSmTSP7 induced IL-13. 
 
Recombinant rSmLy6B, rSmTSP6 and rSmTSP7 Induce a Th1/Pro-inflammatory Cytokine Profile  
Recombinant schistosomula antigens rSmLy6B, rSmTSP6 and rSmTSP7 induced significant and robust 
pre-treatment cytokine responses characterised by Th1 (IFN-), pro-inflammatory (IL-1β, IL-2, IL-6, IL-
9, IL-12, IL-15, IL-17 and TNF) (Figure 2) and regulatory responses (IL-1ra and IL-10) compared to 
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medium (Figure 3). Moreover, rSmLy6B, rSmTSP6 and rSmTSP7 induced high levels of chemokines 
(Figure S1) and growth factors (Figure S2). Interestingly rSmKK7 and rSmLy6A in contrast were 
associated with much lower responses and suppressed production of IL-17, IL-1ra, bFGF, GMCSF, 
GCSF compared to medium (Figures 2, 3, S1 and S2). 
 
Cytokine, Chemokine and Growth Factor Responses to Schistosomula Antigens Cluster Depending 
on the Antigen 
To provide a more global assessment of responses to schistosomula antigens in S. mansoni-infected 
individuals, cytokine responses were grouped together using spearman correlation as a similarity 
measure, to reduce the number of variables for statistical analyses.  
 
Cytokine responses directed against schistosomula recombinant proteins grouped into six 
clusters: two clusters composed of individual cytokines (an IFN- only cluster A and IL-15 only cluster 
B); two clusters composed of Th1/pro-inflammatory/regulatory response responses to rSmTSP6 and 
rSmTSP7 (clusters C and F); a cluster composed mainly Th1/pro-inflammatory/regulatory response 
mainly to rSmLy6B (cluster D); and a pro-inflammatory cluster in response to rSmKK7, SmLy6A and 
SmLy6B (cluster E) (Figure 4). 
 
Similarly, chemokine responses to the schistosomula antigens clustered around individual 
chemokines (clusters A and C) and an eotaxin/IL-8 cluster in response to all antigens tested. (Figure 
S3A).  
 
Finally, growth factor responses clustered around responses to rSmKK7 and rSmLy6A (cluster 
A), responses to rSmLy6B, rSmTSP6 and rSmTSP7 (cluster B) and a single growth factor cluster for 
PDGFFbb (cluster C) (Figure S3B).  
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Responses to rSmKK7 & rSmLy6A are Positively Associated with Pre-treatment Infection Intensity  
To explore whether clusters of pre-treatment cellular responses were associated with infection 
intensity before or 1 year post-treatment, the global test was performed (32). This test examines the 
association between clusters (e.g. groups of correlated immune parameters) and an outcome (e.g. 
pre-treatment or post-treatment infection intensity). After adjusting for age and sex a significant 
positive association between pre-treatment infection intensity and responses to rSmKK7 and 
rSmLy6a were found for the IFN-γ cytokine cluster (Table 3, p=0.026), for the eotaxin chemokine 
cluster (Table S1, p=0.020)) and a combination of growth factors (Table S2, p=0.015). No significant 
associations were found between clusters of immune response and 1-year post-treatment infection 
intensity (Table 3, S1 and S2).  
 
Discussion  
The schistosomula are vulnerable to host immune responses after transformation from the cercariae 
stage(33,34). As a result, antigens of the early schistosomula have been suggested as potential 
vaccine candidates (21,35). Here we measured cytokine, chemokine and growth factor responses to 
a selection of S. mansoni schistosomula-enriched antigens in endemic subjects with high infection 
intensity, and who become re-infected one year after successful treatment.  
 
To validate our study, we first looked at immune responses to the crude parasite antigen 
preparations AWA and SEA. In line with previous studies amongst individuals from high endemicity 
areas (36–38), we found predominant Th2 cytokine responses characterised by high IL-5 and IL-13. 
 
Few schistosomula antigens have been tested in S. mansoni endemic populations. A non-
inclusive list of these antigens includes Sm29 (also known as SmLy6D) (39) and Sm14 (40,41) that 
have both been tested in Brazil. We found that three of the recombinant schistosomula antigens 
tested (rSmLy6B, rSmTSP6 and rSmTSP7) induced strong Th1/pro-inflammatory and regulatory 
responses while two others (rSmKK7, and rSmLy6A) induced low responses in a Ugandan S. mansoni 
endemic population. Th1 and pro-inflammatory cytokines have been implicated in antibody-
independent killing of schistosomula by stimulating macrophages to produce nitric oxide that 
mediates the killing of schistosomula in animal models (42,43). Although the observed cytokine 
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responses are consistent with a previous study in which a recombinant schistosomulum antigen, 
rSm14, induced significant levels of Th1/pro-inflammatory cytokines at 72 hours after stimulation 
(40), our study shows that these responses can be measured earlier at 24 hours. An early response 
to the schistosomulum is necessary due to its transient nature in the tissues including the skin.  
 
The generation of Th1 responses is associated with protective immunity to S. mansoni (44). 
For instance, the schistosomula antigen SmLy6D (Sm29) induces Th1 and proinflammatory cytokines 
(IFN-, TNF and IL-12) that protect vaccinated mice against challenge infection (45). Furthermore, 
vaccinating mice with a chimera of two recombinant schistosomula antigens SmTSP2 and SmLy6D 
(Sm29) formulated in CpG-Alum also protects vaccinated mice against infection (46). Whether the 
schistosomula antigens used in the present study, SmLy6B, SmTSP6 and SmTSP7, are protective in 
animal models of schistosomiasis remains to be determined. In a study in Brazil, Sm14-specific Th1 
responses were produced by PBMCs of people who were resistant to reinfection with 
schistosomiasis (40). This suggests that high antigen specific Th1 responses may play a protective 
role in human resistance to reinfection. However, with no clear resistant group in our cohort one-
year post-treatment, we instead looked at the association between cytokine responses and infection 
intensity before and after treatment with PZQ. We found no association between infection intensity 
at either pre- or post-treatment and that Th1/pro-inflammatory cytokines to rSmLy6B, rSmTSP6 and 
rSmTSP7 suggesting that in our cohort these responses may not be protective in humans and other 
schistosomula antigenic targets should be explored.  
 
Recombinant SmLy6B, rSmTSP6 and rSmTSP7 induced production of regulatory cytokines IL-
10 and IL-1ra. This is consistent with work done with another schistosomula tegument antigen, 
SmLy6D (Sm29) that induced IL-10 production in PBMCs of S. mansoni-infected individuals (41). In 
fact, the expression of SmLy6D (Sm29) is similar to that of rSmLy6B (16,19) and rSmTSP6 and 
rSmTSP7 (19). The concomitant regulatory responses induced by the recombinant antigens in the 
present study may be needed to balance effector responses to limit immunopathology. This suggests 
that antigens rSmLy6B, rSmTSP6 and rSmTSP7 that induce regulated Th1 responses might be good 
targets to consider further as prospective human vaccine candidates in combination with adjuvants 
to induce a stronger Th1 response. In the present study rSmKK7 did not significantly produce IL-10. 
However, IL-10 has been shown to be elevated in patients stimulated with cercarial excreted 
secreted (ES) products (47) of which SmKK7 is a component (16). This inconsistency suggests that 
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other constituents of cercarial ES material could be the major stimulants of IL-10 production. In fact, 
glycosylated components of cercarial ES may play a role in the production of IL-10 (47). In addition, 
the anomaly in IL-10 production could be caused by a difference in the stimulant used. Turner and 
colleagues used native cercarial ES material released from transforming cercariae (47), while the 
SmKK7 used in the present study is a purified recombinant protein without glycosylated moieties. 
 
Interestingly, rSmTSP7 induced IL-13 production in stimulated PBMCs of infected partipants, 
whereas the other schistosomula antigens did not. In addition, the same rSmTSP7 induced Th1/pro-
inflammatory cytokine production. These findings imply a mixed Th1/Th2 response to recombinant 
schistosomula antigen SmTSP7. As much as murine studies have suggested that Th1 responses 
against migrating larvae may be more host protective than Th2 responses (46,48,49), a mixed 
Th1/Th2 response in mice vaccinated with radiation attenuated cercariae indicates that induction 
and balance of both Th1 and Th2 is required for vaccine induced protection and not a highly 
polarized Th1 or Th2 (50). Unregulated and highly polarized immune responses are responsible for 
the immunopathology associated with schistosomiasis in mice (51) and humans (52). This property 
of rSmTSP7 to induce a regulated mixed Th1/Th2 response positions it as a potential vaccine 
candidate to investigate further. 
 
Recombinant rSmKK7 and rSmLy6A induced low responses and suppressed the production 
of IL-17 and IL-1ra compared to PBMCs cultured in medium alone. rSmKK7 shares homology with a 
venom protein BmKK7 of the Asian scorpion Buthus martensi Karsch (BmK) that blocks potassium 
channels (16,53). As potassium channels are vital in the regulation of T cell activation after antigenic 
stimulation (54), it is possible that SmKK7 affects potassium channels, thereby modulating T cell 
activation and suppressing cytokine production by T cells (16). It remains to be experimentally 
determined if indeed SmKK7 modulates human T cell activation. Furthermore, Th1/pro-
inflammatory immune responses to rSmKK7 and rSmLy6A were positively associated with pre-
treatment infection intensity. However, the suitability of these antigens as vaccine candidates is 
debatable because they elicited low responses and were not associated with protection against S. 
mansoni re-infection. 
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The cytokine responses to the recombinant antigens observed in this study likely reflect the 
differences in the expression of the gene products of the schistosomula antigens, and their 
localisation within the S. mansoni organism. SmLy6B, SmTSP6 and SmTSP7 are localized in the 
tegument and their gene products are highly expressed during the 3-hour, 24-hour, 3-day and 6-day 
schistosomula as well as adult life stages (17,19); SmLy6A, also a tegument antigen, is only highly 
expressed in the 6-day schistosomula, while SmKK7 is a secreted molecule (16). 
 
Because of the small number of participants in the present analysis, a larger study may be 
warranted to investigate the association between cytokine responses to the schistosomula antigens 
and infection intensity one year after PZQ treatment. Nonetheless, a large number of cytokines was 
evaluated per participant. While this creates a problem of multiple comparisons, the approach taken 
in the present study using unsupervised hierarchical clustering allows for large numbers of 
cytokines/ growth factors/ chemokines to be tested as a group rather than as individual parameters. 
The responses to the crude antigens AWA and SEA were not represented in the cluster analysis of 
response to recombinant schistosomula antigens. The global test in the present study utilised the 
groups of cytokines/ growth factors/ chemokines to find a relationship with either pre-treatment or 
one-year post-treatment infection intensity. The global test allowed for a global analysis of 
responses which may give broader and generalized insights. The global test has been used elsewhere 
to study clusters of microarray gene data and how the gene clusters relate to two types of leukaemia 
(32). In addition, the global test adjusts for multiple comparisons since few groups are tested (32). In 
essence, the global test may be useful for studies of cohorts with many independent measurements. 
 
The rate of exposure to the Schistosoma through water contact is associated with resistance 
to reinfection with schistosomiasis (55–57). It follows that exposure history during follow up is an 
important variable in the understanding of reinfection with schistosomiasis. The participants in the 
present study might have had varied rates of exposure during follow-up, which was not assessed in 
the present study and thus affecting immune responses to schistosomula antigens. To control 
exposure to infection in future immunogenicity studies of vaccine antigens, a controlled human 
infection model (CHIM) for schistosomiasis could be explored. Hitherto the hookworm was the only 
human helminth to be studied in CHIM for its potential as a vaccine (NCT01940757). The first CHIM 
for schistosomiasis is ongoing with European volunteers using a single sex (male cercariae) infection 
to assess safety and optimal dose of such controlled infections (NCT02755324). Based on the 
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findings from this trial, future CHIM for schistosomiasis could investigate human responses to 
promising Schistosoma antigens including schistosomula antigens in endemic populations.  
 
In conclusion, our findings show that the schistosomula antigens rSmLy6B, rSmTSP6 and 
rSmTSP7 induce a predominantly Th1/pro-inflammatory response. The recombinant antigens 
SmLy6B, SmTSP6 and SmTSP7 might be good targets to investigate further as vaccine antigens 
against S. mansoni infection.  
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Tables  
Table 1. The List of recombinant antigens used in the present study  
Name  Alternative 
names 
S. mansoni 
GeneDB 
identification†  
Predictions from 
protein data 
Protein Size 
(amino acids)¶ 
Ref.  
SmKK7  Smp_194830 Signal peptide 
predicted ‡  
No transmembrane 
regions predicted§ 
79 (15,16) 
SmLy6a SmCD59a, 
SmCD59.1 
Smp_019350  One transmembrane 
regions predicted§ 
126 (13,20) 
SmLy6b SmCD59b, 
SmCD59.2 
Smp_105220  One transmembrane 
regions predicted§ 
124 (13,20,21) 
SmTSP6  
 
 Smp_059530 Four transmembrane 
regions predicted§ 
196 (18,19) 
SmTSP7  Smp_099770 Four transmembrane 
regions predicted§ 
225 (18,19) 
† GeneDB is an annotation database for pathogens (58). 
‡ Determined using SignalP  
§ Determined using TMHMM 
¶ Protein data retrieved from GeneDB 
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Table 2. Characteristics of Study Population (N=54) 
Age, median (range) 12 (6-40) 
Females, n (%) 28 (52) 
Pre-treatment infection intensity  
Light (1-99 epg), n (%) 7 (13) 
Moderate (100-399 epg), n (%) 6 (11) 
Heavy (400+ epg), n (%) 41 (76) 
1-year follow-up infection intensity  
Light (1-99 epg), n (%) 31 (57) 
Moderate to heavy (100+ epg), n (%) 23 (43) 
epg, eggs per gram 
 
Table 3. Association Between Clusters of Cytokine Responses to Schistosomula Antigens and Pre-
treatment Infection Intensity 
Cluster† Pre-treatment Infection Intensity‡ 1-Year Post-treatment Infection 
Intensity‡ 
Crude Adjusted§ Crude Adjusted§ 
A 0.010¶ 0.026¶ 0.060 0.131 
B 0.663 0.746 0.550 0.853 
C 0.189 0.312 0.178 0.363 
D 0.496 0.134 0.262 0.481 
E 0.307 0.140 0.810 0.946 
F 0.578 0.427 0.912 0.866 
† Clusters are shown in Figure 4 
‡ Global Test p-value 
§ Adjusted for age and sex 
¶ Positive direction of association 
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Figure Legends  
Figure 1 Box-Cox transformed Th2 cytokine levels in response to stimulation of PBMCs from S. 
mansoni infected participants (n=54) before PZQ treatment with AWA, SEA and schistosomula 
antigens compared with medium (A) IL-5 (B) IL-13. Box and whisker plots show median, interquartile 
range, maximum and minimum of cytokine levels. A paired Student’s T-test was used to test 
differences between medium and antigens. * p<0.05, ** p<0.007, *** p<0.001, **** p<0.0001 
Figure 2 Box-Cox transformed Th1 (A-B) and pro-inflammatory (C-I) cytokine levels in response to 
stimulation of PBMCs from S. mansoni infected participants (n=54) before PZQ treatment with AWA, 
SEA and schistosomula antigens compared with medium. Box and whisker plots show median, 
interquartile range, maximum and minimum of cytokine levels. A paired Student’s T-test was used to 
test differences between medium and antigens. * p<0.05, ** p<0.007, *** p<0.001, **** p<0001 
Figure 3 Box-Cox transformed regulatory cytokine levels in response to stimulation of PBMCs from S. 
mansoni infected participants (n=54) before PZQ treatment with AWA, SEA and schistosomula 
antigens compared with medium (A) IL-1ra and (B) IL-10. Box and whisker plots show median, 
interquartile range, maximum and minimum of cytokine levels. A paired Student’s T-test was used to 
test differences between medium and antigens. * p<0.05, ** p<0.007, *** p<0.001, **** p<0.0001 
Figure 4 Unsupervised hierarchical clustering of cytokine responses from PBMCs of S. mansoni 
infected participants (n=54) before PZQ treatment stimulated with S. mansoni schistosomula 
antigens. Red and blue colors indicate strong positive and negative correlations respectively. 
 
 
 
Supplementary Figures 
Figure S1 Box-Cox transformed chemokine levels in responses to stimulation with AWA, SEA and 
schistosomula antigens compared with medium (A) IP-10 (B) IL-8 (C) Eotaxin (D) MCP-1. Box and 
whisker plots show median, interquartile range, maximum and minimum of cytokine levels. A paired 
Student’s T-test was used to test differences between medium and antigens. * p<0.05, ** p<0.007, 
*** p<0.001, **** p<0.0001 
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Figure S2 Box-Cox transformed growth factor levels in response to stimulation with AWA, SEA and 
schistosomula antigens compared with medium (A) bFGF (B) GMCSF (C) GCSF (D) PDGFbb (E) VEGF. 
Box and whisker plots show median, interquartile range, maximum and minimum of cytokine levels. 
A paired Student’s T-test was used to test differences between medium and antigens. * p<0.05, ** 
p<0.007, *** p<0.001, **** p<0.0001 
 
Figure S3 Unsupervised hierarchical clustering of (A) chemokine and (B) growth factor responses to 
S. mansoni schistosomula antigens using Spearman correlation as a measure of similarity. Red and 
blue colors indicate strong positive and negative correlations respectively  
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